Published in AIDS Weekly, March 29th, 1999
Known as a Phase III trial, the DPH/UCSF study focuses on the ability of the test vaccine to protect the body against HIV infection. It is part of a three-year, multi-site clinical research effort that is the first in the U.S. to look specifically at this aspect of a test vaccine.
The test vaccine is produced through genetic engineering techniques, so it is a synthetic product and does not contain any live...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.